The bar is set very high in terms of the biosimilar requirement definition, and physicians who are hesitant about substituting biosimilars for treatment should not be worried about the perceived ...

Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America In total, 95% of respondents could identify the most appropriate definition of ...

For diseases like diabetes and certain cancers, biologic medicines have revolutionized care for patients. But the complexities around delivering these medicines to patients have resulted in lengthy ...

Biosimilars offer the potential to deliver substantial cost savings in biologic therapy and to contribute to increased patient access to biologic treatments, both of which are particularly relevant ...

Two policy strategies have been pursued to moderate spending on infused cancer biologics. The competition strategy seeks to stimulate market entry by biosimilars, under the principle that newer ...

Please provide your email address to receive an email when new articles are posted on . “Biosimilars” are a relatively new concept to many physicians in the U.S., and an extensive inventory of ...

Biosimilars are biopharmaceuticals that have been assessed by regulatory agencies to have efficacy and safety similar to their reference products and are expected to be marketed at substantially lower ...

There is substantial disparity between Medicare Part D and employer-sponsored health insurance plans in the coverage of biosimilars and their reference biologics. These disparities may be due to ...

Biological products, or biologics, are large, complex molecules produced in living systems such as therapeutic proteins, antibodies, and gene- or cell-based therapies. Under the Public Health Service ...

Biosimilars are often promoted as cost-saving alternatives to their reference medications. Designed to provide comparable therapeutic efficacy at a reduced price, they have the potential to lower ...

When US regulators approved a new drug called Zarxio in March, it became the first FDA-approved biosimilar: a "copy" of a medication made from living things. Drugs derived from biological substances ...